Antibody-drug conjugates: Converting our expanding knowledge base into successful immunotherapeutics



Antibody-drug conjugates: Converting our expanding knowledge of disease and immune system biology into successful immunotherapeutics


Antibody-drug conjugates, or ADCs, are a class of exciting new therapeutics that utilize the patient’s own immune system, with the antibody delivering the drug right to the disease site

There are two ADCs currently being used to treat lymphoma and breast cancer in patients, with dozens more in clinical development. Yet challenges remain, and new tools and methods must be designed to deal with them.

This white paper discusses:

  • Early clinical failures of ADCs and what was learned from those failures
  • Selecting the tumor antigen target in ADC development
  • How monoclonal antibodies serve as vehicles to deliver a drug to the disease site

Read the white paper.

To access the complimentary white paper 'Antibody-drug conjugates: Converting our expanding knowledge base into successful immunotherapeutics', please fill in the form below.


Elsevier's R&D Solutions for Drug Discovery & Development

PharmaPendium

Make more informed drug development decisions on safety and efficacy, risk assessments and mitigation, and study designs by providing researchers with searchable FDA/EMA drug approval documents and comparative drug safety data.
Learn more about PharmaPendium
Contact a PharmaPendium expert

Professional Services

Drive innovative pharmaceutical research by resolving challenges with data quality and integration and making data easier for researchers to compare, analyze, interpret and share.

Learn more about Professional Services
Contact a Professional Services expert